Cure8 research brief
This study gives real-world comparative data on two biologic options (vedolizumab vs anti-TNFα) used early in the treatment course for Crohn’s disease, which may help patients and clinicians weigh effectiveness and safety when choosing first- or second-line biologics.
Clinicians treating Crohn’s disease, adult patients considering or on biologic therapy, and researchers studying biologic sequencing or real-world outcomes.
This abstract reports results from EVOLVE-IBERIA, a retrospective real-world study comparing vedolizumab with anti-TNFα agents when used as first- or second-line biologics in adults with Crohn’s disease treated in Spain and Portugal.
The study reviewed medical charts (210 Crohn’s patients) with a median follow-up of about 26 months and used propensity-score weighting to adjust comparisons. At 52 weeks, clinical response rates were similar between groups; remission appeared numerically higher with anti-TNFα but the difference did not reach conventional statistical significance.
Reported treatment-related adverse events were lower with vedolizumab than with anti-TNFα agents. This is an observational, chart-review study rather than a randomized trial, so differences may be influenced by residual confounding despite statistical adjustment.
The article provides real-world effectiveness and safety data relevant to treatment sequencing decisions but does not establish causality.
This is a retrospective chart-review (observational) study with propensity-score adjustment; such designs can reduce but not eliminate confounding. Findings are from Spain and Portugal and reflect routine practice settings rather than randomized assignment.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
